遠大醫藥(00512.HK)附屬擬向保定九孚購買5210萬元原材料
格隆匯12月24日丨遠大醫藥(00512.HK)發佈公告,於2019年12月24日,武漢科諾(一間公司間接擁有91.6%的附屬公司)與保定九孚訂立了採購協議,據此武漢科諾同意向保定九孚購買原材料,累計代價約人民幣5210萬元。
武漢科諾是一間於中國成立的股份制有限責任,是一間公司間接擁有91.6%的附屬公司,主要從事研發、生產及銷售生物農藥、生物肥料、微生物飼料添加劑原料及其製劑。
保定九孚是一間於中國成立的有限責任公司,由中國遠大持有約71%及獨立第三方持有約29%,連同其附屬公司主要從事生產及銷售高端甾體化合物。
公司稱,根據採購協議進行採購的產品包括多種原材料(包括一種獨家產品),可用於生產動物飼料級的抗生素。訂立採購協議將可使該集團產品維持高品質以及所需要的原材料的穏定供應,使該集團可執行其業務策略及降低營運風險。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.